Poisbeau P.,University of Strasbourg |
Keller A.F.,University of Strasbourg |
Keller A.F.,Rhenovia Pharma |
Aouad M.,University of Strasbourg |
And 3 more authors.
Frontiers in Cellular Neuroscience | Year: 2014
A growing number of studies indicate that 3-alpha reduced neurosteroids are remarkable analgesics in various pain states. This is the case for allopregnanolone (AP), one of the most potent endogenous positive allosteric modulators of GABAA receptor function. From the pioneering work of Hans Selye, who described the sedative properties of steroids, synthetic compounds resembling the progesterone metabolite AP have been developed. If some of them have been used as anesthetics, it seems difficult to propose them as a therapeutic option for pain since they display several adverse side effects such as sedation, amnesia and functional tolerance. An alternative strategy, chosen by few laboratories around the world, is aimed at stimulating the local production of 3-alpha reduced neurosteroids in order to limit these well-known side effects. This pharmacological approach has the advantage of targeting specific structures, fully equipped with the necessary biosynthetic enzymatic machinery, where neurosteroids already act as endogenous pain modulators. The various pharmacological trials which attempted to treat pain symptoms by stimulating the production of 3-alpha reduced neurosteroids are reviewed here, as well as novel neurotransmitter systems possibly regulating their endogenous production. © 2014 Poisbeau, Keller, Aouad, Kamoun, Groyer and Schumacher.
Rhenovia Pharma | Date: 2013-01-30
A transdermal device (1) comprising at least one substrate (2) arranged to be applied against the dermal surface or the mucous membrane. The at least one active ingredient is grafted to the substrate (2) by at least one photolabile ligand, and at least one light source (11) operated by a control mechanism arranged to generate light pulses, of a predetermined wavelength, intended to break covalent bonds between the active ingredient and the ligand in order to release the active ingredient from the substrate (2). The substrate (2) comprises at least one porous matrix (6) with a three-dimensional structure comprising a plurality of pits (7) organized in a sponge-like fashion and constructed of a polymer chosen between chitin and chitosan, and the matrix (6) defines at least one three-dimensional tank (8). The active ingredient is contained and grafted by the ligand.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: NMP.2012.1.3-2 | Award Amount: 1.39M | Year: 2013
MOD-ENP-TOX project is a multidisciplinary project aiming to accomplish the following objectives: (i) to develop a novel and rational Modelling Assay Platform (MAP) which can be used as a Risk Indicator tool to predict the toxicity of metal-based NPs (MeNPs), and (ii) to demonstrate the feasibility of a MAP prototype on a shortlist of MeNPs - which can be further developed to screen the toxicity of a large number ENPs. Based on the concept of Integrating Testing Strategies (ITS), the proposed generic MAP combines two main and complimentary paradigms: (1) a novel Computational Modelling Package (CMP) based on structural, mechanistic, as well as kinetic modelling tools and (2) an innovative high content screening (HCS) strategy that allows performing multiplexed streamlined assays for calibration, refinement and validation of the computed models. First a series of classification algorithms will be applied to identify MeNPs with similar toxicity patterns, then computational modelling tools will be developed to establish a more rational relationship between MeNPs descriptors and their toxicity in a dynamic and quantitative way. An in-vitro/in-vivo HCS paradigm will be developed as a scalable assessment tool to calibrate and validate the predictive power of the CMP using subsets of the training set or independent set of MeNPs (validation set) respectively.
News Article | July 30, 2015
According to a new market research report "Biosimulation Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by Application (Drug Discovery & Development, Preclinical, Clinical Trial), by End Users - Global Forecast to 2020", published by MarketsandMarkets, the Biosimulation Market is expected to reach USD 2,107.99 million by 2020 from USD 1,034.93 million in 2015, at a CAGR of 15.29%. Browse more than 75 market data Tables, 64 Figures spread through 150 Pages and in-depth TOC on "Global Biosimulation Market". Early buyers will receive 10% customization on this report. The global Biosimulation Market is poised to witness rapid growth between 2015 and 2020. A strong trend of R&D investments in biotechnology and pharmaceutical industries will majorly drive the Biosimulation Market. Other growth drivers include the need to curtail costs, growth in the biologics and biosimilars markets, and increased use of personalized medicine, technological advancements, and periodic product upgradation. The market is segmented on the basis of product, application, and end user. By product, the market includes software and services. The software segment is further classified into molecular modeling and simulation software, PBPK modeling and simulation software, PK/PD modeling and simulation software, trail design software, toxicity prediction software, and other software (QSP, visualizing and analytical software). The services segment includes in-house and external/contract services. Software will hold the largest share of the Biosimulation Market in 2015, while services will grow at the highest CAGR. The applications included in this report are drug discovery, drug development, and others. The drug development segment is further classified into preclinical testing and clinical trials. The drug discovery segment is divided into target identification & validation and lead identification & optimization. The drug development segment will hold the largest share of the Biosimulation Market in 2015. The other applications segment (defense, industrial bioprocessing, nutraceuticals, and agri-food production) is expected to be the fastest growing. End users included in this report are academic and government research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities and other end users (defense, nutraceuticals companies, and food and agricultural companies). Of these, the pharmaceutical and biotechnology companies will hold the largest share of the Biosimulation Market in 2015. Pharmaceutical and biotechnology companies are expected to form the fastest-growing end-user segment. The geographic segments included in this report are the North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to hold the largest share of this market in 2015, while Europe is expected to grow at the fastest rate. Growth in the European Biosimulation Market will primarily be driven by increased government funding and the large number of pharmaceuticals and biotechnology companies in this region. Major players in the global Biosimulation Market are Certara USA, Inc. (U.S.), Simulation Plus Inc. (U.S.), Dassault Systèmes SA (France), Schrödinger Inc. (U.S.), Advanced Chemistry Development, Inc. (Canada), Chemical Computing Group, Inc. (Canada), Physiomics PLC (U.K.), Entelos Holding Corporation (U.S.), Rhenovia Pharma Ltd. (France), and Genedata AG (Switzerland). Healthcare/Medical Simulation Market by Product (Patient Simulator, Surgical Simulator, Web-based simulation, Simulation Software, Dental Simulator, Eye Simulator), End-User (Academics, Hospitals, Military) & by Services - Global Forecast to 2019 MarketsandMarkets is world's No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. Contact: Mr. Rohan 4400 NE 77th Avenue, Suite 275, Vancouver, Washington 98662, United States, Tel: + 1-888-600-6441 Email: firstname.lastname@example.org Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/pharmaceuticals Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets
News Article | February 12, 2014
Rhenovia Pharma, a Mulhouse, France, and Cambridge, Massachusetts, USA-based biotechnology company specialized in the application of biosimulation to the research and development of new medicinal products, raised €540k (approximately $738k) in a second round of funding. The company, which plans to raise a further €2m in 2014, intends to use the funds to expand its staff, particularly in the areas of marketing and therapeutic applications. Founded in 2007, Rhenovia uses its technology to create computer simulators that predict the effect of molecules both on healthy patients and others living with conditions such as Alzheimer’s disease, Parkinson’s disease, epilepsy and depression, reducing the need for animal testing. Its technology can also measure the effects of neurotoxic agents such as pesticides, nanoparticles, industrial emissions and chemical weapons and help in the development of antidotes to poison gas, making it of key interest to stakeholders in civil and military protection. The new round will be open to new investors, particularly family offices to step up development across the three key markets that it already services: pharmaceutical, agrifood and neurotoxicity. The company has around twenty members of staff in France, Switzerland, Germany and the US.
News Article | December 16, 2016
— Huntington Disease - Companies Involved in Therapeutics Development are Addex Therapeutics Ltd, AFFiRiS AG, Angita BV, Annexon Inc, Astellas Pharma Inc, Azevan Pharmaceuticals Inc, BioCrea GmbH, BrainStorm Cell Therapeutics Inc, Celon Pharma Sp z oo, Chong Kun Dang Pharmaceutical Corp, Diffusion Pharmaceuticals Inc, EncephRx Inc, Evotec AG, Galenea Corp, Genervon Biopharmaceuticals LLC, Horizon Pharma Plc, Immungenetics AG, Ionis Pharmaceuticals Inc, Ipsen SA, Kadmon Corp LLC, KineMed Inc, Krenitsky Pharmaceuticals Inc, Living Cell Technologies Ltd, Medesis Pharma SA, Mitochon Pharmaceuticals Inc, Neuralstem Inc, Neurimmune Holding AG, NeuroNascent Inc, New World Laboratories Inc, nLife Therapeutics SL, NsGene A/S, Omeros Corp, Oryzon Genomics SA, Pfizer Inc, PharmatrophiX Inc, ProQR Therapeutics NV, QR Pharma Inc, reMYND NV, Retrotope Inc, Rhenovia Pharma Ltd, Shire Plc, SOM Biotech SL, Spark Therapeutics Inc, Teva Pharmaceutical Industries Ltd, TyrNovo Ltd, Ultragenyx Pharmaceutical Inc, UniQure NV, Vaccinex Inc, Vertex Pharmaceuticals Inc, VistaGen Therapeutics Inc, Vitality Biopharma Inc, VivaCell Biotechnology Espana SL, Voyager Therapeutics Inc, Vybion Inc, WAVE Life Sciences Ltd and Wellstat Therapeutics Corp. Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10, 5, 46 and 17 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 19 and 4 molecules, respectively. Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Inquire more about this report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=786898 Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. • The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System). • The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/786898-huntington-disease-pipeline-review-h2-2016.html
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: NMP-2008-2.1-1 | Award Amount: 5.21M | Year: 2009
The aim of SELFMEM is to develop innovation in the field of nanoporous membranes. This will be achieved by taking advantage of the self-assembly properties of block copolymers leading to highly porous membranes with adjustable, regular-sized pores of tailored functionalities. Both polymeric and inorganic (silicon) membranes will be developed. In the case of isoporous polymeric membranes focus will be laid on the formation of integral-asymmetric block copolymer membranes with an isoporous top layer as a function of the block copolymer structure and the preparation conditions. Isoporous inorganic membranes will be prepared by using a thin block copolymer film as a mask for selective etching. The possibilities to systematically vary the pore size and density by varying the block copolymer mask structure will be investigated. The block copolymers will be synthesized by controlled polymerisation techniques (anionic, group transfer, and different radical polymerisations), depending on the chosen monomers. The characterisation during and after formation of the membranes will be carried out by light and various x-ray scattering techniques, by scanning force microscopy, and by different electron microscopic techniques. Both types of membranes will be post-functionalized in order to tune their final properties. The membranes will be tested for their applicability in different areas. Separation of gases (like H2/CO2) and proteins as well as water purification will be addressed in this project. Modeling and theory will support the understanding of the structure formation of these membranes and help to optimise membrane design. The results of SELFMEM will increase European competitiveness in strategic markets such as gas purification, water treatment and molecular biology. The consortium consists of 12 partners from 10 countries, including 4 companies from 3 countries.
News Article | December 6, 2016
This report studies the Global Biosimulation Market, analyzes and researches the Biosimulation development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Certara Simulation Plus Dassault Systèmes Schr?dinger Advanced Chemistry Development Chemical Computing Group Entelos Genedata Ag Physiomics PLC Rhenovia Pharma Market segment by Application, Biosimulation can be split into Application 1 Application 2 Application 3 United States, EU, Japan, China, India and Southeast Asia Biosimulation Market Size, Status and Forecast 2021 1 Industry Overview of Biosimulation 1.1 Biosimulation Market Overview 1.1.1 Biosimulation Product Scope 1.1.2 Market Status and Outlook 1.2 Global Biosimulation Market Size and Analysis by Regions 1.2.1 United States 1.2.2 EU 1.2.3 Japan 1.2.4 China 1.2.5 India 1.2.6 Southeast Asia 1.3 Biosimulation Market by End Users/Application 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 2 Global Biosimulation Competition Analysis by Players 2.1 Biosimulation Market Size (Value) by Players (2015-2016) 2.2 Competitive Status and Trend 2.2.1 Market Concentration Rate 2.2.2 Product/Service Differences 2.2.3 New Entrants 2.2.4 The Technology Trends in Future 3 Company (Top Players) Profiles 3.1 Certara 3.1.1 Company Profile 3.1.2 Main Business/Business Overview 3.1.3 Products, Services and Solutions 3.1.4 Biosimulation Revenue (Value) (2011-2016) 3.1.5 Recent Developments 3.2 Simulation Plus 3.2.1 Company Profile 3.2.2 Main Business/Business Overview 3.2.3 Products, Services and Solutions 3.2.4 Biosimulation Revenue (Value) (2011-2016) 3.2.5 Recent Developments 3.3 Dassault Systèmes 3.3.1 Company Profile 3.3.2 Main Business/Business Overview 3.3.3 Products, Services and Solutions 3.3.4 Biosimulation Revenue (Value) (2011-2016) 3.3.5 Recent Developments 3.4 Schr?dinger 3.4.1 Company Profile 3.4.2 Main Business/Business Overview 3.4.3 Products, Services and Solutions 3.4.4 Biosimulation Revenue (Value) (2011-2016) 3.4.5 Recent Developments 3.5 Advanced Chemistry Development 3.5.1 Company Profile 3.5.2 Main Business/Business Overview 3.5.3 Products, Services and Solutions 3.5.4 Biosimulation Revenue (Value) (2011-2016) 3.5.5 Recent Developments 3.6 Chemical Computing Group 3.6.1 Company Profile 3.6.2 Main Business/Business Overview 3.6.3 Products, Services and Solutions 3.6.4 Biosimulation Revenue (Value) (2011-2016) 3.6.5 Recent Developments 3.7 Entelos 3.7.1 Company Profile 3.7.2 Main Business/Business Overview 3.7.3 Products, Services and Solutions 3.7.4 Biosimulation Revenue (Value) (2011-2016) 3.7.5 Recent Developments 3.8 Genedata Ag 3.8.1 Company Profile 3.8.2 Main Business/Business Overview 3.8.3 Products, Services and Solutions 3.8.4 Biosimulation Revenue (Value) (2011-2016) 3.8.5 Recent Developments 3.9 Physiomics PLC 3.9.1 Company Profile 3.9.2 Main Business/Business Overview 3.9.3 Products, Services and Solutions 3.9.4 Biosimulation Revenue (Value) (2011-2016) 3.9.5 Recent Developments 3.10 Rhenovia Pharma 3.10.1 Company Profile 3.10.2 Main Business/Business Overview 3.10.3 Products, Services and Solutions 3.10.4 Biosimulation Revenue (Value) (2011-2016) 3.10.5 Recent Developments For more information or any query mail at [email protected]
News Article | November 15, 2016
Bio Simulation Technology Market is estimated at $1.01 billion in 2015 and is projected to reach $2.99 billion by 2022 growing at a CAGR of 16.6% from 2015 to 2022. Reduction in the cost of drug discovery and development and risk of failure of drug molecule are some of the factors driving the market growth. Furthermore, R&D investments in biotechnology and pharmaceutical industries, growth in the biologics and biosimilars markets, increased use of personalized medicines, technological advancements and periodic product upgradation are the key factors vitalizing the market growth. However, lack of standardization, high R&D costs associated with development of biosimulation software and lack of skilled professionals are some of the major restraints hampering the market growth. Industrial bioprocessing, nutraceuticals, agri-food production and biosimulation in the defense will provide opportunities for market growth over the forecast period. Pharmaceutical and biotechnology companies segment is valued to account largest share across the global market. North America is anticipated to command the largest share and Europe is expected to register the highest growth due to increasing government funding and the large number of pharmaceuticals and biotechnology companies in this region. Some of the key players in this market include Certara USA Inc., Simulation Plus Inc., Dassault Systèmes SA, Schrödinger Inc., Advanced Chemistry Development Inc., Chemical Computing Group Inc., Entelos Holding Corporation, Genedata Ag, Physiomics PLC, Rhenovia Pharma Ltd., Insilico biosciences, Archimedes, Insilico biotechnology, Accelrys, LeadScope and Compugen. Application Covered: • Application In Drug Development o Clinical Trials o Preclinical Testing • In Patient Validation • Application In Drug Discovery o Target Validation o Target Identification o Lead Identification/Discovery o Lead Optimization Product Covered: • Software o Toxicity Prediction Software o Molecular Modeling and Simulation Software o Trial Design Software o PK/PD Modeling and Simulation Software o Pbpk Modeling and Simulation Software o Other Software • Services o External/Contract Services o In-House Services Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Us Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.